Literature DB >> 15152266

Cytosine arabinoside induces costimulatory molecule expression in acute myeloid leukemia cells.

R Vereecque1, A Saudemont, B Quesnel.   

Abstract

Chemotherapeutic drugs kill cancer cells mainly by direct cytotoxicity, but they might also induce a stronger host immune response by causing the tumor to produce costimulatory cell surface molecules like CD80. We previously reported that in myeloid leukemic cells, gamma-irradiation induced CD80 expression. In this study, we show that cytosine arabinoside (Ara-C), even at low doses, induced CD80 expression in vitro in mouse DA1-3b leukemic cells, by a mechanism that involved reactive oxygen species. In vivo experiments in the mouse DA1-3b/C3H whole-animal acute myeloid leukemia (AML) model showed that injection of Ara-C induced expression of CD80 and CD86, and decreased expression of B7-H1, indicating that chemotherapy can modify costimulatory molecule expression in vivo, in a way not necessarily observed in vitro. Mouse leukemic cells exposed in vivo to Ara-C were more susceptible to specific cytotoxic lymphocyte (CTL)-mediated killing. Ara-C also induced CD80 or CD86 expression in 14 of 21 primary cultured human AML samples. In humans being treated for AML, induction chemotherapy increased CD86 expression in the leukemic cells. These findings indicate possible synergistic strategies between CTL-based immunotherapy and chemotherapy for treatment. They also suggest an additional mechanism by which chemotherapy can eradicate AML blasts.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15152266     DOI: 10.1038/sj.leu.2403391

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  22 in total

Review 1.  Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy.

Authors:  Enrico Proietti; Federica Moschella; Imerio Capone; Filippo Belardelli
Journal:  Mol Oncol       Date:  2011-12-03       Impact factor: 6.603

Review 2.  DNA Damage and Repair Biomarkers of Immunotherapy Response.

Authors:  Kent W Mouw; Michael S Goldberg; Panagiotis A Konstantinopoulos; Alan D D'Andrea
Journal:  Cancer Discov       Date:  2017-06-19       Impact factor: 39.397

Review 3.  Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled.

Authors:  Jan Philipp Bewersdorf; Maximilian Stahl; Amer M Zeidan
Journal:  Expert Rev Anticancer Ther       Date:  2019-03-19       Impact factor: 4.512

4.  Disulfide-stabilized diabody antiCD19/antiCD3 exceeds its parental antibody in tumor-targeting activity.

Authors:  Li Wei; Fan Dongmei; Yang Ming; Shi Ruizan; Yan Yan; Jiang Linlin; Yan Cihui; Li Shuangjing; Wang Min; Wang Jianxiang; Xiong Dongsheng
Journal:  Cell Oncol (Dordr)       Date:  2012-10-09       Impact factor: 6.730

5.  Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.

Authors:  Farhad Ravandi; Rita Assi; Naval Daver; Christopher B Benton; Tapan Kadia; Philip A Thompson; Gautam Borthakur; Yesid Alvarado; Elias J Jabbour; Marina Konopleva; Koichi Takahashi; Steven Kornblau; Courtney D DiNardo; Zeev Estrov; Wilmer Flores; Sreyashi Basu; James Allison; Padmanee Sharma; Sherry Pierce; Allison Pike; Jorge E Cortes; Guillermo Garcia-Manero; Hagop M Kantarjian
Journal:  Lancet Haematol       Date:  2019-08-07       Impact factor: 18.959

Review 6.  Chemoimmunotherapy: reengineering tumor immunity.

Authors:  Gang Chen; Leisha A Emens
Journal:  Cancer Immunol Immunother       Date:  2013-02-07       Impact factor: 6.968

Review 7.  Chemotherapy and tumor immunity: an unexpected collaboration.

Authors:  Leisha A Emens
Journal:  Front Biosci       Date:  2008-01-01

8.  Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule.

Authors:  Hazem Ghebeh; Cynthia Lehe; Eman Barhoush; Khaldoon Al-Romaih; Asma Tulbah; Monther Al-Alwan; Siti-Faujiah Hendrayani; Pulicat Manogaran; Ayodele Alaiya; Taher Al-Tweigeri; Abdelilah Aboussekhra; Said Dermime
Journal:  Breast Cancer Res       Date:  2010-07-13       Impact factor: 6.466

9.  In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors.

Authors:  Céline Berthon; Virginie Driss; Jizhong Liu; Klaudia Kuranda; Xavier Leleu; Nathalie Jouy; Dominique Hetuin; Bruno Quesnel
Journal:  Cancer Immunol Immunother       Date:  2010-09-04       Impact factor: 6.968

10.  Cytosine arabinoside promotes cytotoxic effect of T cells on leukemia cells mediated by bispecific antibody.

Authors:  Wei Li; DongMei Fan; Ming Yang; Yan Yan; RuiZan Shi; JunPing Cheng; ZhenZhen Li; MengNan Zhang; JianXiang Wang; Dongsheng Xiong
Journal:  Hum Gene Ther       Date:  2013-08       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.